Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 14fludarabine 8Rituximab 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Vincristine 4Doxorubicin 4Dexamethasone 4zanubrutinib 3Prednisone 3Nivolumab 3Etoposide 3tazemetostat 2tafasitamab 2pirtobrutinib 2pembrolizumab 2glofitamab 2etoposide phosphate 2cemiplimab 2acalabrutinib 2Leukapheresis 2Immunotherapy, Adoptive 2Immunoglobulin G 2Gemcitabine 2Disulfides 2Cisplatin 2Cell- and Tissue-Based Therapy 2Biopsy 2venetoclax 1varlilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × loncastuximab tesirine × 30 days × Clear all
NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

University of Washington

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡